PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Boulding sold 2,812 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $61.88, for a total value of $174,006.56. Following the completion of the sale, the vice president owned 105,272 shares of the company's stock, valued at approximately $6,514,231.36. This trade represents a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Elliott Boulding also recently made the following trade(s):
- On Friday, October 9th, Mark Boulding sold 192 shares of PTC Therapeutics stock. The stock was sold at an average price of $64.26, for a total value of $12,337.92.
- On Monday, October 5th, Mark Boulding sold 1,638 shares of PTC Therapeutics stock. The stock was sold at an average price of $64.03, for a total value of $104,881.14.
- On Tuesday, October 6th, Mark Boulding sold 435 shares of PTC Therapeutics stock. The shares were sold at an average price of $64.16, for a total value of $27,909.60.
PTC Therapeutics Stock Down 0.2%
Shares of NASDAQ:PTCT traded down $0.13 during trading on Wednesday, reaching $60.23. The stock had a trading volume of 642,752 shares, compared to its average volume of 1,332,788. PTC Therapeutics, Inc. has a 52 week low of $58.80 and a 52 week high of $90.87. The firm has a market capitalization of $5.03 billion, a price-to-earnings ratio of -43.02, a P/E/G ratio of 4.47 and a beta of 0.52. The stock has a fifty day simple moving average of $63.78 and a two-hundred day simple moving average of $70.12.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of $0.14 by ($0.76). The firm had revenue of $357.81 million for the quarter, compared to analyst estimates of $306.43 million. The company's revenue was up 69.6% compared to the same quarter last year. During the same period last year, the firm earned $0.20 EPS. On average, analysts forecast that PTC Therapeutics, Inc. will post 0.49 EPS for the current year.
PTC Therapeutics declared that its Board of Directors has approved a stock repurchase program on Tuesday, November 3rd that permits the company to buy back $500 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 9.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board believes its shares are undervalued.
Hedge Funds Weigh In On PTC Therapeutics
Several large investors have recently bought and sold shares of PTCT. BlackRock Inc. bought a new position in PTC Therapeutics during the second quarter worth about $1,139,089,000. Jupiter Topco LLC bought a new stake in shares of PTC Therapeutics in the 2nd quarter valued at approximately $590,182,000. Janus Henderson Group PLC grew its stake in shares of PTC Therapeutics by 48.3% in the 1st quarter. Janus Henderson Group PLC now owns 7,193,433 shares of the biopharmaceutical company's stock valued at $489,997,000 after purchasing an additional 2,342,101 shares during the period. Wellington Management Group LLP raised its holdings in shares of PTC Therapeutics by 4.7% in the 2nd quarter. Wellington Management Group LLP now owns 4,128,273 shares of the biopharmaceutical company's stock worth $336,743,000 after buying an additional 185,663 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of PTC Therapeutics by 31.8% in the 1st quarter. Bank of America Corp DE now owns 1,886,841 shares of the biopharmaceutical company's stock worth $128,550,000 after buying an additional 455,284 shares in the last quarter.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on PTCT shares. Wells Fargo & Company boosted their target price on shares of PTC Therapeutics from $109.00 to $112.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Weiss Ratings raised PTC Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, October 8th. Citigroup raised their price target on PTC Therapeutics from $108.00 to $109.00 and gave the company a "buy" rating in a research report on Monday, November 2nd. Zacks Research lowered PTC Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 6th. Finally, Truist Financial assumed coverage on PTC Therapeutics in a research report on Friday, October 16th. They set a "hold" rating and a $62.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $99.23.
Check Out Our Latest Report on PTC Therapeutics
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PTC Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.
While PTC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.